07 Jan 2019

MEDTRONIC GETS OK TO STUDY PATIENTS WITH BICUSPID AORTIC VALUES USING COREVALVE EVOLUT TAVR SYSTEM

The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for Medtronic to initiate a single-arm study to evaluate the CoreValve Evolut TAVR system in patients with bicuspid aortic valves who are at low risk of surgical mortality. Medtronic separately received FDA approval for revised commercial

0
05 Jan 2019

AS HOSPITALS POST STICKER PRICES ONLINE, MOST PATIENTS WILL REMAIN BEFUDDLED

    By Julie Appleby and Barbara Feder Ostrov As of Jan. 1, in the name of transparency, the Trump administration required that all hospitals post their list prices online. But what is popping up on medical center websites is a dog’s breakfast of medical codes, abbreviations and dollar signs — in little

0
05 Jan 2019

IT’S A LITTLE-KNOWN SECRET THAT PATIENTS CAN GET THOUSANDS OF DOLLARS DIRECTLY FROM A DRUGMAKER

      By Sarah Jane Tribble   Kip Burgess was relieved last year when pharmaceutical giant Amgen overnighted him a $2,976 check to help pay for his go-to arthritis drug, Enbrel. The 36-year-old psychologist had run into an increasingly common problem: The copay coupon sent by Thousand Oaks, Calif.-based Amgen

0
03 Jan 2019

IN.PACT ADMIRAL:  MEDTRONIC SHARES FIVE-YEAR DRUG-COATED BALLOON DATA

  Medtronic plc data presented Nov. 12 reinforce the durability, safety, and effectiveness of the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral artery disease in the superficial femoral and popliteal arteries. The five-year and final results from the pivotal IN.PACT SFA Trial and one-year all-subjects results from the

0
03 Jan 2019

KENNETH OSORIO, MD: A successful vein specialist leads missions of mercy to Caraz, Peru

  By John A. Chuback, MD, FACS, RPVI, RVT, RPhS   Kenneth Osorio, MD, is a successful phlebologist and the medical director of Advanced Vein Center, a very active clinical practice in Mesa, Arizona. Despite his many professional accomplishments, he has not forgotten his roots; nor has Dr. Osorio forgotten

0
02 Jan 2019

SCHAENING ACP KEYNOTE: 2019 LCD DRAFTING,  NOTIFICATION, REVISION TO BE MORE TRANSPARENT

  By Vanessa Salvia Juan Schaening, MD, the executive contractor medical director for Medicare Jurisdiction N, discussed changes to 2019 Local Coverage Determinations during a keynote address at the American College of Phlebology’s 32nd Annual Congress Nov. 9 in Nashville. He said changes are designed to provide transparency in the

0
02 Jan 2019

IMPROVING WISELY: COLLABORATION HELPS IDENTIFY, CUT HEALTHCARE WASTE

By Vanessa Salvia In the elegant Presidential Ballroom of the Gaylord Opryland Resort in Nashville, Martin “Marty” Makary, MD, addressed American College of Phlebology’s 32nd Annual Congress attendees eager to hear his message about how the program Improving Wisely is helping to reduce waste in healthcare. More than 1,200 registrants,

0
31 Dec 2018

BOSTON SCIENTIFIC LINES UP FINANCING FOR ITS $4B BTG ACQUISITION

Now that everyone has said yes, Boston Scientific has gone to the banks to sign a number of new lending agreements, including a large credit facility it could use to finance its $4.2 billion acquisition offer for British medical device maker BTG plc. The information, which came from recently posted

0
20 Dec 2018

MCAFEE: CRYPTOMINING AND IoT MALWARE BOTH ROSE OVER 70% IN Q3 2018

    By DeanTakahashi VentureBeat   Cybersecurity firm McAfee said that the cybercriminal underworld is generating 480 new threats per minute. That’s one of the details in the new McAfee Labs Threats Report: December 2018.   McAfee reported that internet of things malware was up 73 percent in the third quarter, while cryptocurrency

0
12 Dec 2018

VEIN CLINICS OF AMERICA NAMES ALTON SHADER TO PRESIDENT AND CEO POST

Alton Shader, formerly president of Hill-Rom’s global Front Line Care business, has been named president and CEO of Vein Clinics of America (VCA), a Frazier Healthcare Partners  portfolio company, replacing Hans Thunem. A VCA release indicated that Thunem, who was CEO for four years, made the decision earlier in 2018

0